Dr. Vehling-Kaiser MVZ GmbH
- Address
- lock Available on a paid plan
Hematology and Lymphatic Disorders
At Dr. Vehling-Kaiser MVZ GmbH in Landshut, clinical research in Hemic and Lymphatic Diseases focuses on chronic lymphocytic leukemia and Richter transformation, with studies aimed at improving treatment effectiveness and outcomes for patients with difficult-to-treat blood cancers.
- Evaluating new combination treatments for CLL with Richter transformation
- Studying retreatment strategies to better control recurring disease
- Assessing survival and response in advanced hematologic malignancies
This research area reflects a strong interest in testing more effective therapies for aggressive and relapsed blood cancers.
Breast Cancer Research
The site is also active in Neoplasms research, especially breast cancer, including ER+/HER2- early breast cancer and advanced HER2-negative, hormone receptor-positive breast cancer. These studies are designed to improve recurrence prevention and support better long-term disease control.
- Testing endocrine-based approaches to reduce the risk of breast cancer recurrence
- Exploring treatment options for advanced hormone receptor-positive disease
- Looking at how patients respond to targeted cancer therapies over time
The research in this field combines treatment optimization with a focus on maintaining effectiveness after standard care.
Lung Cancer and Respiratory Oncology
In Respiratory Tract Diseases, the clinical trials at this German research site include metastatic lung adenocarcinoma, with attention to patients whose tumors have specific molecular features such as TTF-1 negativity. The goal is to compare treatment approaches and identify more effective options for advanced lung cancer.
- Comparing different cancer treatment combinations for advanced lung adenocarcinoma
- Studying survival outcomes in metastatic respiratory tract cancer
- Seeking better therapies for patients with limited standard options
This work supports the development of more personalized treatment strategies in lung cancer care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr. Vehling-Kaiser MVZ GmbH
lock Showing 1 of 27 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Amgen Inc. | Phase I | Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 5 | Unknown | 2021-11-11 | 2025-08-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.